| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/16/2023 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant | Stock Option (right to buy) | 25k | $2.79 | $69.6k | | 08/16/2023 |
| 08/16/2023 | Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | Grant | Stock Option (right to buy) | 136.5k | $2.79 | $380.2k | | 08/16/2023 |
| 08/16/2023 | Frankenfield Christopher James | COO | Grant | Stock Option (right to buy) | 300k | $2.79 | $835.5k | | 08/16/2023 |
| 08/16/2023 | Russo Rene | CEO | Grant | Stock Option (right to buy) | 700k | $2.79 | $1.9M | | 08/16/2023 |
| 08/03/2023 | Frankenfield Christopher James | COO | Grant | Stock Option (Right to Buy) | 150k | $2.75 | $412.5k | | 08/03/2023 |
| 04/01/2023 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | Grant | Stock Option (right to buy) | 55k | $3.17 | $174.4k | | 04/01/2023 |
| 01/01/2023 | English Edward C | PRINCIPAL ACCOUNTING OFFICER | Grant | Stock Option (right to buy) | 24k | $2.69 | $64.6k | | 01/01/2023 |
| 01/01/2023 | Russo Rene | CEO | Grant | Stock Option (right to buy) | 350k | $2.69 | $941.5k | | 01/01/2023 |
| 01/01/2023 | Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | Grant | Stock Option (right to buy) | 136.5k | $2.69 | $367.2k | | 01/01/2023 |
| 09/15/2022 | Heyman Tomas J. | Director | Grant | Stock Option (right to buy) | 26.4k | $3.15 | $83.2k | | 09/15/2022 |
| 06/15/2022 | Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | Grant | Stock Option (right to buy) | 20k | $2.28 | $45.6k | | 06/15/2022 |
| 06/15/2022 | ROSS ROBERT W. | Director | Grant | Stock Option (right to buy) | 26.4k | $2.28 | $60.2k | | 06/15/2022 |
| 06/15/2022 | Ross Michael Jay | Director | Grant | Stock Option (right to buy) | 13.2k | $2.28 | $30.1k | | 06/15/2022 |
| 06/15/2022 | Clancy Paul J | Director | Grant | Stock Option (right to buy) | 13.2k | $2.28 | $30.1k | | 06/15/2022 |
| 06/15/2022 | Xu Yuan | Director | Grant | Stock Option (right to buy) | 13.2k | $2.28 | $30.1k | | 06/15/2022 |
| 06/15/2022 | Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | Grant | Stock Option (right to buy) | 20k | $2.28 | $45.6k | | 06/15/2022 |
| 06/15/2022 | Rossi Christina | Director | Grant | Stock Option (right to buy) | 13.2k | $2.28 | $30.1k | | 06/15/2022 |
| 06/15/2022 | Bonstein Sara | Director | Grant | Stock Option (right to buy) | 13.2k | $2.28 | $30.1k | | 06/15/2022 |
| 02/22/2022 | Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | Grant | Stock Option (right to buy) | 65k | $12.66 | $822.9k | | 02/22/2022 |
| 02/22/2022 | Russo Rene | CEO | Grant | Stock Option (right to buy) | 150k | $12.66 | $1.9M | | 02/22/2022 |
| 02/22/2022 | Giovine Salvatore | CFO | Grant | Stock Option (right to buy) | 49.5k | $12.66 | $626.7k | | 02/22/2022 |
| 01/04/2022 | Xu Yuan | Director | Grant | Stock Option (right to buy) | 26.4k | $15.92 | $420.3k | | 01/04/2022 |
| 12/22/2021 | Russo Rene | CEO | Grant | Stock Option (right to buy) | 100k | $13.83 | $1.4M | | 12/22/2021 |
| 12/22/2021 | Russo Rene | CEO | Grant | Stock Option (right to buy) | 100k | $13.83 | $1.4M | | 12/22/2021 |
| 12/10/2021 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | Common Stock | 21.8k | $9.56 | $208.6k | See footnotes | 12/08/2021 |
| 12/10/2021 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | Common Stock | 3.2k | $10.24 | $32.6k | See footnotes | 12/08/2021 |
| 12/09/2021 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | Common Stock | 4k | $9.84 | $39.5k | See footnotes | 12/08/2021 |
| 12/08/2021 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | Common Stock | 13.5k | $9.62 | $129.5k | See footnotes | 12/08/2021 |
| 10/26/2021 | Merck KGaA | 10% Owner | Conversion | Series C Preferred Srock | 2.5M | $0.00 | $0 | See Footnote | 10/26/2021 |
| 10/26/2021 | Flynn James E | 10% Owner | Conversion | Common Stock | 756.5k | $0.00 | $0 | Through Deerfield Partners, L.P. | 10/26/2021 |
| 10/26/2021 | Flynn James E | 10% Owner | Purchase | Common Stock | 387.5k | $16.00 | $6.2M | Through Deerfield Partners, L.P. | 10/26/2021 |
| 10/26/2021 | Flynn James E | 10% Owner | Conversion | Series C Preferred Stock | 7.2M | $0.00 | $0 | Through Deerfield Partners, L.P. | 10/26/2021 |
| 10/26/2021 | RiverVest Venture Fund IV, L.P. | 10% Owner | Conversion | Common Stock | 832.1k | $0.00 | $0 | See Footnotes | 10/26/2021 |
| 10/26/2021 | Merck KGaA | 10% Owner | Conversion | Common Stock | 416.1k | $0.00 | $0 | See Footnote | 10/26/2021 |
| 10/26/2021 | Merck KGaA | 10% Owner | Conversion | Common Stock | 264.8k | $0.00 | $0 | See Footnote | 10/26/2021 |
|